Polycystic Ovary Syndrome in the Pediatric Population
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common disorder characterized by hyperandrogenism and disordered gonadotropin secretion, often associated with insulin resistance. The syndrome, which modulates both hormonal and metabolic processes, is the most common endocrinopathy in reproductive-age women and increases a woman's risk of infertility, endometrial pathology, and cardiometabolic disease. As it is currently defined, PCOS most likely encompasses several distinct diseases with similar clinical phenotypes but different underlying pathophysiological processes. However, hyperandrogenism remains the syndrome's clinical hallmark. The clinical manifestations of PCOS often emerge during childhood or in the peripubertal years, suggesting that the syndrome is influenced by fetal programming and/or early postnatal events. However, given that the full clinical spectrum of PCOS does not typically appear until puberty, a "two-hit" hypothesis has been proposed: (1) a girl develops hyperandrogenism via one or more of many different potential mechanisms; (2) the preexisting hyperandrogenism subsequently disturbs the hypothalamic–pituitary–ovarian axis, resulting in ovulatory dysfunction and sustained hyperandrogenism. No consensus guidelines exist regarding the diagnosis and management of PCOS in the pediatric population; however, because the syndrome is a diagnosis of exclusion, the clinical evaluation of girls suspected of having PCOS is aimed at excluding other causes of androgen excess and menstrual dysfunction. For the syndrome's management, emphasis is placed on lifestyle and symptom-directed treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 2×
“However, the 2006 Androgen Excess Society (AES) definition reemphasized the importance of hyperandrogenism in the etiology of PCOS, requiring: (1) The absence of other hyperandrogen-causing disorders, syndromes of severe insulin resistance, thyroid dysfunction, and hyperprolactinemia, (2) hyperandrogenism (clinical an…”
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 1×
“The 2009 Androgen Excess and Polycystic Ovary Syndrome Society’s definition also emphasized the importance of hyperandrogenism in the syndrome’s etiology, requiring: (1) Hyperandrogenism (clinical and/or biochemical), (2) ovarian dysfunction (oligo- or anovulation and/ or polycystic ovaries), and (3) the exclusion of…”
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 1×
“The thiazolidinediones (TZDs) (troglitazone, rosiglitazone, and pioglitazone) are another class of insulin-sensitizing agents that act as agonists for the nuclear peroxisome proliferator-activated receptor g (PPARg).(259,260) Like metformin, they improve peripheral insulin sensitivity, androgen levels, and ovulatory f…”
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome — An allostatic perspective
Virtue, S., & Vidal-Puig, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.12.006 · Cited by 1,013
Kiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Maternal nutrition, fetal nutrition, and disease in later life
Barker, D. J. P. (1997) · Nutrition · doi:10.1016/s0899-9007(97)00193-7 · Cited by 849
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704
Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Ehrmann, D. A., Liljenquist, D. R., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1329 · Cited by 703
Perseghin, G., Price, T. B., Petersen, K. F., Roden, M., Cline, G. W., Gerow, K., Rothman, D. L., & Shulman, G. I. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610313351804 · Cited by 699
Menstruation in girls and adolescents: using the menstrual cycle as a vital sign
American Academy of Pediatrics, Committee on Adolescence, American College of Obstetricians and Gynecologists, & Committee on Adolescent Health Care (2006) · PEDIATRICS · doi:10.1542/peds.2006-2481 · Cited by 651
Clark, A. M., Ledger, W., Galletly, C., Tomlinson, L., Blaney, F., Wang, X., & Norman, R. J. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a135772 · Cited by 642
Dunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561 · cited 14×
“Hirsutism, the most common cutaneous sign of hyperandrogenism, appears to be progressive in women with PCOS.”
InfluentialNelson, V. L., Legro, R. S., Strauss, J. F., & McAllister, J. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0311 · Cited by 556
Abbott, D. H., Barnett, D. K., Bruns, C. M., & Dumesic, D. A. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi013 · Cited by 555 · cited 1×
“In addition, intrauterine androgen exposure in these monkeys leads to the development of insulin resistance associated with visceral adiposity, impaired glucose metabolism, and dyslipidemia.(101) The above observations in both humans and monkeys thus support a potential role of epigenetics and fetal programming in the…”
Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0628 · Cited by 537 · cited 1×
“In the United States alone, it is also associated with an economic burden exceeding four billion dollars.(9) PCOS is primarily characterized by: (1) Menstrual dysfunction (oligo- or amenorrhea), (2) cutaneous signs of hyperandrogenism (acne, hirsutism, or alopecia), (3) obesity, (4) disordered gonadotropin [luteinizin…”
Moran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Developmental origin of polycystic ovary syndrome—a hypothesis
Abbott, D., Dumesic, D., & Franks, S. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740001 · Cited by 504 · cited 1×
“Moreover, several lines of evidence suggest a developmental origin of the syndrome.(39,40) In particular, studies from nonhuman primates have shown that prenatal exposure to androgen excess in utero leads to the Table 1.”
Zhang, L. H., Rodriguez, H., Ohno, S., & Miller, W. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10619 · Cited by 455
Chung, B. C., Picado-Leonard, J., Haniu, M., Bienkowski, M., Hall, P. F., Shively, J. E., & Miller, W. L. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.2.407 · Cited by 444
Holte, J., Bergh, T., Berne, C., Wide, L., & Lithell, H. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673399 · Cited by 435
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426 · cited 2×
“Metformin inhibits hepatic glucose production and increases peripheral tissue insulin sensitivity,(247) and in women with PCOS, appears to improve insulin sensitivity, insulin and androgen levels, lipid parameters, and menstrual cyclicity.(245,246,248) Moreover, it is effective in reducing the incidence of diabetes in…”
Expression of Bovine 17α-Hydroxylase Cytochrome P-450 cDNA in Nonsteroidogenic (COS 1) Cells
Zuber, M. X., Simpson, E. R., & Waterman, M. R. (1986) · Science · doi:10.1126/science.3535074 · Cited by 388
ADASHI, E. Y., HSUEH, A. J. W., & YEN, S. S. C. (1981) · Endocrinology · doi:10.1210/endo-108-4-1441 · Cited by 366
HAISENLEDER, D. J., DALKIN, A. C., ORTOLANO, G. A., MARSHALL, J. C., & SHUPNIK, M. A. (1991) · Endocrinology · doi:10.1210/endo-128-1-509 · Cited by 355
Screening for Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome
Palmert, M. R., Gordon, C. M., Kartashov, A. I., Legro, R. S., Emans, S. J., & Dunaif, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8305 · Cited by 354 · cited 1×
“Furthermore, overweight and obese girls with PCOS are at increased risk for impaired glucose metabolism and have a greater than threefold increased risk of developing type 2 diabetes later in life.(210) Thus, in the natural history of PCOS, environmental influences (mainly diet and physical inactivity leading to obesi…”
Longitudinal study of physiologic insulin resistance and metabolic changes of puberty
Hannon, T. S., Janosky, J., & Arslanian, S. A. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000246097.73031.27 · Cited by 353 · cited 1×
“Specifically, a physiologic increase in insulin resistance and androgen levels occurs in response to growth hormone (GH) secretion, which peaks during adolescence(125); this then leads to an increase in insulin and a decrease in SHBG concentrations, both of which may exacerbate the clinical manifestations of hyperandr…”
Ibañez, L., Potau, N., Virdis, R., Zampolli, M., Terzi, C., Gussinyé, M., Carrascosa, A., & Vicens-Calvet, E. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501168 · Cited by 341
Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336
Progesterone Modulation of Pulsatile Luteinizing Hormone Secretion in Normal Women*
SOULES, M. R., STEINER, R. A., CLIFTON, D. K., COHEN, N. L., AKSEL, S., & BREMNER, W. J. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-58-2-378 · Cited by 319
Barnes, R. B., Rosenfield, R. L., Ehrmann, D. A., Cara, J. F., Cuttler, L., Levitsky, L. L., & Rosenthal, I. M. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.5.7962325 · Cited by 304 · cited 2×
“In fact, studies suggest that the fetal ovary is indeed capable of synthesizing androgens in utero,107 and clinical and biochemical manifestations of PCOS have been noted in young adults with nonclassic CAH.108 Furthermore, even if the fetal ovary does not produce enough androgen to cause prenatal virilization, it may…”
Previs, S. F., Withers, D. J., Ren, J.-M., White, M. F., & Shulman, G. I. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006490200 · Cited by 291
Identifying Children at Risk for Polycystic Ovary Syndrome
Rosenfield, R. L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2012 · Cited by 288 · cited 2×
“First, premature adrenarche, a term used to describe an early increase in adrenal androgen production before 8 years in girls (and 9 years in boys), has been linked to the development of PCOS and metabolic syndrome during adolescence.(17,33,111) The increased androgen production associated with adrenarche, which has b…”
Carmina, E., Chu, M. C., Longo, R. A., Rini, G. B., & Lobo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2279 · Cited by 274
Arslanian, S. A., Lewy, V., Danadian, K., & Saad, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8398 · Cited by 272
Huber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269
Hoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., & Guzick, D. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0461 · Cited by 256
The regulation of 17,20 lyase activity
Miller, W. L., Auchus, R. J., & Geller, D. H. (1997) · Steroids · doi:10.1016/s0039-128x(96)00172-9 · Cited by 227
Ibáñez, L., Potau, N., Zampolli, M., RiquÉ, S., Saenger, P., & Carrascosa, A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4084 · Cited by 199 · cited 2×
“This latter effect would not only increase the availability of free insulin, but also the availability of free IGF-1, which can also stimulate androgen production.(113,170) Furthermore, insulin may contribute to mid-antral follicular arrest,(171) a characteristic feature of the polycystic ovary.”
Oligoanovulation with Polycystic Ovaries But Not Overt Hyperandrogenism
Dewailly, D., Catteau-Jonard, S., Reyss, A.-C., Leroy, M., & Pigny, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1054 · Cited by 198 · cited 1×
“First, using menstrual irregularity to diagnose PCOS is difficult in adolescents, given that greater than 50% of menstrual cycles are anovulatory in the first 2 years after menarche.(22,23) However, menstrual irregularity for more than 2 years after menarche is not considered physiological and is predictive of continu…”
Auchus, R. J., & Miller, W. L. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.7.0326 · Cited by 185
Abbott, D. H., Tarantal, A. F., & Dumesic, D. A. (2009) · American Journal of Primatology · doi:10.1002/ajp.20679 · Cited by 177
Neuroendocrine dysfunction in polycystic ovary syndrome
Burt Solorzano, C. M., Beller, J. P., Abshire, M. Y., Collins, J. S., McCartney, C. R., & Marshall, J. C. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.007 · Cited by 173
Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth
Diamanti-Kandarakis, E., & Piperi, C. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi025 · Cited by 167 · cited 1×
“5).(110) First, premature adrenarche, a term used to describe an early increase in adrenal androgen production before 8 years in girls (and 9 years in boys), has been linked to the development of PCOS and metabolic syndrome during adolescence.”
Sensitization to Insulin Induces Ovulation in Nonobese Adolescents with Anovulatory Hyperandrogenism
Ibáñez, L., Valls, C., Ferrer, A., Marcos, M. V., Rodriguez-Hierro, F., & de Zegher, F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7756 · Cited by 162
Fassnacht, M., Schlenz, N., Schneider, S. B., Wudy, S. A., Allolio, B., & Arlt, W. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021875 · Cited by 158
Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency.
Speiser, P. W., Serrat, J., New, M. I., & Gertner, J. M. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.6.1464643 · Cited by 143
Adult polycystic ovary syndrome begins in childhood
Franks, S. (2002) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2002.0203 · Cited by 142
Cussons, A. J., Watts, G. F., Burke, V., Shaw, J. E., Zimmet, P. Z., & Stuckey, B. G. A. (2008) · Human Reproduction · doi:10.1093/humrep/den263 · Cited by 140 · cited 1×
“Girls diagnosed with hyperandrogenism should then also be screened for other metabolic abnormalities (such as hypertension [using the appropriate age- and height-percentile reference values], dyslipidemia, and impaired glucose metabolism) given the approximately four-fold increased risk of metabolic syndrome in adoles…”
Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.
Korytkowski, M. T., Mokan, M., Horwitz, M. J., & Berga, S. L. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.11.7593446 · Cited by 140 · cited 1×
“The estrogen component both suppresses LH secretion (and thus ovarian androgen production) and increases hepatic SHBG production (decreasing the amount of free testosterone); the progestin component protects the endometrium from unopposed estrogen.(236) Combined OCPs also inhibit 5a-reductase in the skin, decreasing i…”
Bremer, A. A., Auinger, P., & Byrd, R. S. (2009) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2009.21 · Cited by 132 · cited 1×
“Increased physical activity also decreases insulin resistance and has been associated with improved indices of insulin sensitivity in the pediatric population.(229)”
Self-citationAndrogen synthesis in adrenarche
Miller, W. L. (2009) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9102-4 · Cited by 127
Randomized Placebo-Controlled Trial of Metformin for Adolescents With Polycystic Ovary Syndrome
Bridger, T., MacDonald, S., Baltzer, F., & Rodd, C. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.3.241 · Cited by 126
Indices of low-grade inflammation in polycystic ovary syndrome
DIAMANTI‐KANDARAKIS, E., PATERAKIS, T., & KANDARAKIS, H. A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.015 · Cited by 112
The prognosis for adolescents with menstrual abnormalities
Southam, A. L., & Richart, R. M. (1966) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(66)90398-x · Cited by 111 · cited 1×
“However, menstrual irregularity for more than 2 years after menarche is not considered physiological and is predictive of continued irregularity.(24) Second, nonpathologic acne and mild hirsutism are common in the peripubertal years.”
Clinical spectrum of premature pubarche: Links to metabolic syndrome and ovarian hyperandrogenism
Ibáñez, L., Díaz, R., López-Bermejo, A., & Marcos, M. V. (2009) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9096-y · Cited by 106 · cited 2×
“Second, rapid weight gain in small for gestational age (SGA) girls in the first few years of life and sustained adiposity in large for gestational age (LGA) girls during childhood accelerate the prepubertal appearance of PCOS, characterized by visceral obesity, insulin resistance, and premature adrenarche/pubarche.(17…”
Polycystic Ovary Syndrome in Adolescence
Blank, S. K., Helm, K. D., McCartney, C. R., & Marshall, J. C. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1429.005 · Cited by 97 · cited 3×
“Unfortunately for the affected adolescent, it may take up to 12 months to reverse the androgen-induced transformation of vellus to terminal hairs and see clinical improvement in hirsutism due to the prolonged growth cycle of hair.(25) Eflornithine cream (Vaniqa ), an inhibitor of ornithine decarboxylase, is another op…”
Influential
Cited by
State-of-the-science of endocrine disrupting chemicals, 2012
Bergman, Å., Heindel, J., Jobling, S., Kidd, K., & Zoeller, R. T. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.03.020 · Cited by 1,388
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Potential role and therapeutic interests of myo-inositol in metabolic diseases
Croze, M. L., & Soulage, C. O. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.011 · Cited by 578
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
“Although PCOS can occur at any age, beginning with menarche, the majority of instances are identified between the ages of 20 and 30 [7].”
BackgroundA brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS)
Siddiqui, S., Mateen, S., Ahmad, R., & Moin, S. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02625-7 · Cited by 347
Metadata
- Authors
- Bremer, A. A.
- Venue
- Metabolic Syndrome and Related Disorders
- Publisher
- SAGE Publications
- Published
- 2010-10
- Volume
- 8
- Issue
- 5
- Pages
- 375-394
- ISSN
- 1540-4196 (ISSN-L)
- 1557-8518
- OpenAlex
- W2002111609
- Cited by
- 94
- References
- 66
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.